🩺 Shield Therapeutics: Specialty Pharma Focused on Iron Deficiency
Shield Therapeutics is a commercial-stage pharmaceutical company specialising in iron deficiency treatment. Its lead product, Accrufer® / Feraccru® (ferric maltol), is marketed in the UK, US, and licensed across China, Korea, Canada, and other regions.
📈 Share Price & Market Performance
- Current Share Price: 7.00p
- 52-Week Range: 2.10p – 8.50p
- Market Capitalisation: ~£84.2 million
- 1-Year Return: +59.1%
- Recent Movement: –9.68% on the day
The share price is 17.65% below its 52-week high, reflecting volatility despite strong product uptake.
💰 Valuation Metrics
| Metric | Value | Commentary |
|---|---|---|
| P/E Ratio | Not meaningful | Due to negative earnings |
| PEG Ratio | Not available | EPS growth is distorted by restructuring and early-stage commercialisation |
💸 Financial Profile
- EPS (TTM): –1.78p
- Shares Outstanding: ~1.04 billion
- Free Float: ~278 million
- Average Daily Volume: ~7.6 million shares
Shield is still in its growth phase, with losses narrowing as Accrufer gains traction in key markets.
🧠 Strategic Outlook
- Licensing Agreements: Active in China (Aosaikang), Korea (Korea Pharma), and Canada (KYE Pharma)
- Recent Milestones:
- Interim results published 21 August 2025
- Data featured in European Journal of Heart Failure (27 August 2025)
- AGM held in May 2025
Shield is positioning itself as a global leader in iron deficiency therapy, with expanding clinical data and geographic reach.
